(Alliance News) - Clinical-stage biotechnology firm Destiny Pharma PLC on Monday said Joe Eagle, a non-executive director, has stepped down after 18 years on the company's board.
Eagle brought "pharmaceutical and marketing expertise" to the development of Destiny Pharma's XF-73, MRSA-treatment drug candidate, the company said.
He was "instrumental in the financing and strategic direction" of the firm when it was a private company, and made a "considerable contribution" to Destiny Pharma as it transitioned into the AIM market in 2017.
Chair Nick Rodgers said: "On behalf of Destiny Pharma, I would like to thank Eagle for his considerable contribution to the company throughout its development as a private company and the transition onto the AIM market.
"Eagle's understanding of the pharma market and company development has been of great value to Destiny and I am sorry to see him go. We wish him all the very best for the future."
A search for his replacement is underway, the company said.
Shares in Destiny Pharma were 1.2% higher at 41.00 pence each in London on Monday afternoon.
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
Destiny Pharma. (DEST)